The FDA has announced seven Class I recalls related to this issue. Customers are urged to destroy the devices immediately instead of returning them to the manufacturer. 

For years, the ECG market was relatively static. According to a new report, however, things are rapidly changing. 

An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care. 

AF Symposium 2026 in Boston included new data from some of the biggest names in electrophysiology. Johnson & Johnson MedTech, Abbott, Atraverse Medical, Field Medical, Pulse Biosciences, Argá Medtech SA and CardioFocus were just some of the medtech companies at the heart of late-breaking presentations. 

The Impella CP heart pump is being used more and more to treat cardiogenic shock, and the benefits are clear. For many older patients, however, the technology seem to fall short. 

Cardiologist Nathaniel Lebowitz, MD, reviews the latest updates in lipoprotein(a) awareness, testing and drug development.

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC. 

Total plaque volume and total plaque burden can help find patients who may be closer to suffering a heart attack than they realize.

SCAI has shared a new call to action as an observance of American Heart Month. The group is asking Congress to pass new pieces of legislation that could improve care for PAD patients and get important medical devices in the hands of interventional cardiologists.